Company	Price	Valuation					Profitability					Cash & leverage					Quality				Rating
		P/E	P/B	P/S	EV / EBITDA	DCF upside	Gross margin	Operating margin	Net margin	ROE	ROIC	FCF yield	Debt / equity	Net debt / EBITDA	Interest coverage	Current ratio	Dividend yield	Piotroski (0-9)	Altman Z	Rating score (1-5)
BCAXthis companyBicara Therapeutics Inc. Common Stock	$8.83	-6.68×	2.29×	0×	-6×	-79.8%	0.0%	0.0%	0.0%	-34.4%	-38.6%	-11.6%	0×	0.69×	0×	14.58×	0.0%	1	5.84	2	C+
CBIOCrescent Biopharma, Inc.	$14.11	-0.8×	0.61×	11.39×	0.59×	61.0%	100.0%	-1407.5%	-1419.6%	-75.8%	-74.6%	-117.0%	0.01×	1.41×	-69.85×	6.56×	0.0%	3	11.24	2	C+
CGEMCullinan Therapeutics, Inc.	$11.10	-2.78×	1.5×	0×	-2.39×	-90.4%	0.0%	0.0%	0.0%	-53.8%	-58.7%	-28.8%	0.01×	0.39×	0×	10.25×	0.0%	1	9.54	2	C
CMPXCompass Therapeutics, Inc.	$0.78	-12.79×	4.3×	0×	-12.7×	-84.0%	0.0%	0.0%	0.0%	-33.8%	-35.3%	-5.8%	0.05×	0.32×	0×	15.02×	0.0%	3	-0.29	2	C+
CNTXContext Therapeutics Inc.	$0.19	-3.87×	2.31×	0×	-2.05×	231.0%	0.0%	0.0%	0.0%	-59.7%	-65.5%	-18.9%	0×	1.82×	0×	8.52×	0.0%	2	-5.58	3	B
MGNXMacroGenics, Inc.	$2.38	-1.36×	1.83×	0.68×	-2.54×	-2714.5%	71.1%	-48.7%	-49.9%	-134.2%	-33.0%	-81.6%	1.92×	-0.83×	-8.56×	5.1×	0.0%	1	-4.43	1	D+
Peer median	—	-2.78×	1.83×	0×	-2.39×	-84.0%	0.0%	0.0%	0.0%	-59.7%	-58.7%	-28.8%	0.01×	0.39×	0×	8.52×	0.0%	2	-0.29	2	—